DNA-PK Inhibitor based DNA Damage Response targeting Therapeutic Development Service
Introduction What We Can Offer Workflow Why Creative Biolabs Customer Reviews FAQs Related Services Contact Us
At Creative Biolabs, we provide comprehensive solutions meticulously designed to streamline your therapeutic development journey, guiding you effectively from initial concept and target validation all the way through to IND-enabling studies. Our service offers a suite of specific deliverables and robust problem-solving capabilities, each precisely tailored to your unique research needs and project complexities. This ensures that every step of your project progresses efficiently, effectively, and with a clear path towards achieving your critical milestones.
Introduction of DNA-PK Inhibitor-based DNA Damage Response-targeting Therapeutic Development Service
DNA double-strand breaks (DSBs), often therapy-induced, are perilous DNA damage. DNA-dependent protein kinase (DNA-PK) is a pivotal component of the cellular DNA Damage Response (DDR), primarily mediating non-homologous end joining (NHEJ) repair. Inhibiting DNA-PK cripples this pathway, sensitizing cancer cells to genotoxic agents. This strategy promises to overcome therapeutic resistance and enhance treatments, evidenced by clinical progression of inhibitors like M3814 and AZD7648, and novel modalities such as miRNAs and antibody-derived radiosensitizers.
Discover how we can help - Request a consultation.
Fig.1 Structure of DNA-PK and its role in NHEJ.1
What We Can Offer
Deep Scientific Expertise
Our multidisciplinary team of expert biologists, medicinal chemists, and pharmacologists possesses profound knowledge of DNA-PK's multifaceted roles in cancer, guiding your project with insightful experimental design from initial target validation through comprehensive preclinical development. This deep understanding allows us to anticipate challenges and devise innovative solutions.
Precision Biomarker Discovery
We employ advanced genomic, proteomic, and bioinformatic analyses to identify predictive and prognostic biomarkers. By analyzing differential drug responses in our advanced preclinical models, we ensure your DNA-PK inhibitor therapies are precisely targeted to the most responsive patient populations, maximizing therapeutic impact and paving the way for stratified clinical trials.
Optimized Compound Development
Through sophisticated medicinal chemistry and iterative structure-activity relationship (SAR) studies, we meticulously enhance your lead compound's properties. Our focus includes improving potency, selectivity against off-targets, solubility for optimal formulation, and bioavailability for effective systemic delivery.
Synergistic Combination Strategies
We excel in identifying and validating optimal combination therapies. By strategically leveraging DNA-PK inhibition, we can significantly sensitize cancer cells to existing chemotherapies and radiotherapy. This approach not only enhances the efficacy of standard treatments but also offers a powerful strategy for overcoming acquired drug resistance.
Core Steps of DNA-PKi-DDR TDS
Highlights
Unrivaled Expertise and Integrated Solutions
Our multidisciplinary team of experts provides an integrated, end-to-end workflow. This holistic approach ensures seamless project progression from hit identification to rigorous in vitro and in vivo efficacy studies, all under one roof.
Accelerated Preclinical-to-Clinical Translation
Creative Biolabs is dedicated to streamlining your path to clinical success. Our clients achieve a 20% reduction in preclinical development timelines, accelerating the journey from promising candidate to clinical trials.
Precision Oncology and Biomarker-Driven Strategies
We specialize in biomarker discovery and translational research to champion precision oncology. We identify predictive biomarkers for patient stratification, ensuring DNA-PK inhibitor therapies are precisely directed to the most responsive patient populations.
Enhanced Therapeutic Efficacy and Synergistic Outcomes
Creative Biolabs excels in identifying and validating optimal combination therapies. By leveraging DNA-PK inhibition to sensitize cancer cells to existing treatments, we achieve an average 35% increase in radiosensitization efficacy.
Experience the Creative Biolabs advantage - Get a quote today.
Customer Reviews
-
Exceptional Synergy
Using Creative Biolabs' service in our research has significantly improved the synergistic effects of our lead compounds with radiotherapy. Their detailed in vitro and in vivo studies provided clear evidence of enhanced tumor cell death, which was critical for our next funding round. - Dr. A***n S.
-
Precision in Biomarker Identification
The expertise of Creative Biolabs in biomarker discovery for DNA-PK inhibitors is unmatched. They helped us identify specific DDR pathway deficits that predict sensitivity to our compounds, allowing us to refine our patient stratification strategy for future clinical trials. - Prof. L***a M.
FAQs
How does Creative Biolabs' service address drug resistance in oncology?
We specifically identify and optimize DNA-PK inhibitors designed to re-sensitize resistant cancer cells to conventional chemotherapies and radiation. Our extensive combination studies pinpoint synergistic strategies, offering a powerful approach to overcome acquired resistance.
How is DNA-PK inhibitor selectivity ensured?
Our lead optimization process is built on rigorous SAR studies and comprehensive kinase profiling. We leverage our deep understanding of DNA-PK's unique structural features compared to other PIKK family members to rationally design compounds with high specificity.
How does your service compare to off-the-shelf DNA-PK inhibitors?
While commercially available DNA-PK inhibitors serve as basic research tools, we provide an integrated, end-to-end therapeutic development solution. Our service encompasses comprehensive hit identification, iterative lead optimization, in-depth preclinical efficacy and safety assessment, and crucial biomarker support, all tailored precisely to your project's unique needs.
Related Services
Creative Biolabs offers a suite of complementary services to support your entire drug discovery and development pipeline.
Target Validation
For projects requiring initial target identification and robust assay setup, we provide comprehensive services from target characterization to the development and validation of highly specific biochemical and cell-based assays.
Learn More →
Preclinical Oncology Models
We offer services utilizing syngeneic, xenograft, and patient-derived xenograft models across various cancer types, providing robust in vivo data that closely mimics human disease and supports informed decision-making for your therapeutic candidates.
Learn More →
Biomarker Discovery
For comprehensive identification and validation of predictive and prognostic biomarkers, our team employs advanced genomic, proteomic, and bioinformatic approaches.
Learn More →
How to Contact Us
Creative Biolabs is your trusted partner in advancing precision oncology. Our DNA-PK inhibitor-based DNA damage response-targeting therapeutic development service provides an integrated, expert-driven approach to discover, optimize, and validate novel therapeutic candidates. Ready to discuss your project and accelerate your DNA-PK inhibitor development? Contact us.
Reference
-
Matsumoto, Yoshihisa. "Development and evolution of DNA-dependent protein kinase inhibitors toward cancer therapy." International Journal of Molecular Sciences 23.8 (2022): 4264. Distributed under an Open Access license CC BY 4.0, without modification. DOI: https://doi.org/10.3390/ijms23084264
For Research Use Only | Not For Clinical Use
